Patents by Inventor Kimiho Yamada

Kimiho Yamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IMMUNESUPPRESSANT RECEPTOR
    Publication number: 20180118797
    Abstract: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 3, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tomoyuki ODANI, Hideaki TADA, Kimiho YAMADA
  • Use of immunesuppressant receptor
    Patent number: 9856299
    Abstract: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 2, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tomoyuki Odani, Hideaki Tada, Kimiho Yamada
  • USE OF IMMUNESUPPRESSANT RECEPTOR
    Publication number: 20150093383
    Abstract: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tomoyuki ODANI, Hideaki TADA, Kimiho YAMADA
  • Use of immunesuppressant receptor
    Patent number: 8945557
    Abstract: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tomoyuki Odani, Hideaki Tada, Kimiho Yamada